People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scorpion Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $1.4B | 2024 |
| Checkmate Pharmaceuticals, Inc. | — | Biotechnology | Series C | $185.1M | $3.5B | 2019 |
| Antares Therapeutics, Inc. | — | Biotechnology | Series B | $70.0M | $149.6M | 2025 |
| Strata Oncology, Inc. | — | Pharma | Series A | $29.2M | $27.0M | 2018 |
| C-Reveal Therapeutics Llc | — | Biotechnology | Seed | $3.3M | $111.4M | 2020 |
Keith Flaherty at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith Flaherty on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 2 | 17 |
| Shelley Chu | 2 | 10 |
| Adam Friedman | 2 | 6 |
| Jeffrey Albers | 2 | 3 |
| Brian Piper | 2 | 2 |
| Andrew Fedder | 2 | 2 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Robert Weisskoff | 1 | 12 |
| David Rubin | 1 | 11 |
| Jeffrey Williams | 1 | 10 |
| James Pavlik | 1 | 9 |
| Ben Auspitz | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| Gary Glick | 1 | 7 |
| Jan Garfinkle | 1 | 7 |
| Arjun Goyal | 1 | 5 |
| Alan Fuhrman | 1 | 5 |
| William Burkoth | 1 | 5 |
| Nicole Walker | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.